Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PENELOPE: Pertuzumab in platinum-resistant ovarian cancer
NCT01684878Phase 3Completed
- Sponsor
- Roche
- Start
- Oct 2012
- Primary completion
- Jan 2015
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 3 trial of pertuzumab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Roche. Started Oct 2012; status: completed.
02
Drugs
pertuzumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT01684878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01684878.